In 2023, personnel expenses include the compensation of the Chairman of the Management Board and related expenses.
They also include, in the amount of euro 55,856 thousand in 2023, the costs associated with free share and stock option plans, the delivery of which in the form of existing shares entails an expense in the income statement. In 2022, these costs amounted to euro 65,219 thousand.
| (in thousands of euros) | 2023 | 2022 |
|---|---|---|
| Dividends | Dividends 2023 912,459 |
Dividends 2022 90,056 |
| Other income from investments | Other income from investments 2023 1,438 |
Other income from investments 2022 1,703 |
| Investment income | Investment income 2023 913,897 |
Investment income 2022 91,759 |
| Other financial income | Other financial income 2023 1,883 |
Other financial income 2022 2,546 |
| Foreign exchange gains | Foreign exchange gains 2023 262 |
Foreign exchange gains 2022 401 |
| Interest and other financial income | Interest and other financial income 2023 2,145 |
Interest and other financial income 2022 2,946 |
| Reversal of impairment for marketable securities | Reversal of impairment for marketable securities 2023 2 |
Reversal of impairment for marketable securities 2022 83 |
| Reversal of financial provisions & expenses transfers | Reversal of financial provisions & expenses transfers 2023 2 |
Reversal of financial provisions & expenses transfers 2022 83 |
| Total financial income | Total financial income 2023 916,044 |
Total financial income 2022 94,788 |
| Bond‑related amortization | Bond‑related amortization 2023 (2,500) |
Bond‑related amortization 2022 (2,683) |
| Increase in provisions for foreign exchange losses | Increase in provisions for foreign exchange losses 2023 - |
Increase in provisions for foreign exchange losses 2022 - |
| Increase in provisions for impairment of marketable securities | Increase in provisions for impairment of marketable securities 2023 - |
Increase in provisions for impairment of marketable securities 2022 (2) |
| Increase in other financial provisions | Increase in other financial provisions 2023 (25,000) |
Increase in other financial provisions 2022 (5) |
| Amortization and increases in provisions | Amortization and increases in provisions 2023 (27,500) |
Amortization and increases in provisions 2022 (2,690) |
| Bond‑related interests | Bond‑related interests 2023 (11,845) |
Bond‑related interests 2022 (12,250) |
| Other financial interests | Other financial interests 2023 (95,743) |
Other financial interests 2022 (53,743) |
| Foreign exchange losses | Foreign exchange losses 2023 (229) |
Foreign exchange losses 2022 (466) |
| Interest and other financial expenses | Interest and other financial expenses 2023 (107,817) |
Interest and other financial expenses 2022 (66,459) |
| Total financial expenses | Total financial expenses 2023 (135,317) |
Total financial expenses 2022 (69,149) |
| Net financial income | Net financial income 2023 780,727 |
Net financial income 2022 25,639 |
Net non recurring items for the 2023 financial year are not material, representing a loss of euro 3 thousand. It should be noted that it includes exceptional income and exceptional expense of the same amount for euro 120.8 million linked to the comprehensive resolution that has been reached with all 50 State Attorneys General, the District of Columbia, and certain US territories related to past work undertaken for opioid manufacturers primarily by former advertising agency Rosetta (merged with Publicis Health LLC), bringing to a close almost three years of discussions.
As part of this agreement, and following the settlement made in the United States, Publicis Groupe SA received reimbursements from insurers on behalf of its subsidiary Publicis Health, amounting to euro 120.8 million. At the same time, an accrual for the same amount was recognized with its subsidiary.
Exceptional items for the 2022 financial year resulted in a loss of euro 4,200 thousand, corresponding to a provision for tax litigation.
